Bisfosfonaty: chto my znaem o nezhelatel'nykh yavleniyakh, svyazannykh s ikh primeneniem


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bisphosphonates are widely used for the treatment of osteoporosis and other metabolic bone diseases such as Paget’s disease, multiple myeloma, bone metastases and hypercalcemia in oncological diseases. Their efficacy and safety are well-proven in multicenter studies, but long-term use of bisphosphonates in clinical practice revealed new rare adverse events, possibly associated with their use. This article represents a review of adverse events registered in clinical studies, analysis of the national databases of medical records, and case reports. Due to low incidence of serious adverse events in the treatment of osteoporosis, a significant prevalence of positive effects - reducing the risk of osteoporotic fractures of different locations, bisphosphonates remain a first-line drugs for the treatment of osteoporosis worldwide.

Full Text

Restricted Access

About the authors

S. G Anikin

N. V Toroptsova

References

  1. Adami S., Bhalla A.K., Dorizzi R., et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41(6): 326-31.
  2. Olson K., Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007;13(4):223-29.
  3. Dicuonzo G., Vincenzi B., Santini D., et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 2003;23( 11):649-54.
  4. Thompson K., Rogers M.J. Statins prevent bisphos phonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004;19(2):278-88.
  5. Wysowski D.K., Chang J.T. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 2005;165:346-47.
  6. Nakchbandi I.A., Grey A., Masiukewicz U., et al. Cytokines in primary hyperparathyroidism. In:The Parathyroids, Basic and Clinica Concepts. Academic Press, San Diego 2001:411-21.
  7. Bauer D.C., Black D., Ensrud K., et al.Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160(4):51 7-25.
  8. Cadarette S.M., Katz JN., Brookhart M.A., et al. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int 2009; 20:1735-47.
  9. Cryer B., Miller P., Petruschke R.A., Chen E., et al.Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant nonsteroidal anti-inflammatory drug use. Aliment Pharmacol Ther 2005;21(5):599-607.
  10. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360(1):89-90.
  11. Green J., Czanner G., Reeves G., et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010;341:4444. doi: 10.1136/bmj.c4444.
  12. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304(6):657-63.
  13. Solomon D.H., Patrick A., Brookhart M.A. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360(17): 1789-90; author reply 1791-92.
  14. Abrahamsen B., Eiken P., Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360(17):1789; author reply 1791-92.
  15. Nguyen D.M., Schwartz J., Richardson P., El-Serag H.B. Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci 2010;55( 12):3404-407.
  16. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of post-menopausal osteoporosis N Engl J Med 2007; 356(18):1809-22.
  17. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357(18):1 799-809.
  18. Cummings S.R., Schwartz A.V. Alendronate and atrial fibrillation (letter). N Engl J Med 2007;356:1895-96.
  19. Sorensen H.T., Christensen S., Mehnert F., et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008; 33 6(7648):813-16.
  20. Vestergaard P., Schwartz K., Pinholt E., et al. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int 2010;86:335-42.
  21. Loke Y.K., Jeevanantham V., Singh S. Bisphosphonates and atrial fibrillation: systematic review and metaanalysis. Drug Saf 2009;32:219-28.
  22. Kim S.Y., Kim M.J., Cadarette S.M., et al. Bisphosphonates and risk of atrial fibrillation: a meta-analysis. Arthritis Res Ther 2010; 12:R30.
  23. Chatap G., Giraud K., Vincent J.P. Atrial fibrillation in the elderly: facts and management. Drugs Aging 2002;19( 11):819-46.
  24. http:/www.fda.gov/cder/drug/early_comm/ bisphosphonates_update_200811.htm.
  25. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-91.
  26. Edwards B.J., Gounder M., McKoy J.M., et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008;9(12):1166-72.
  27. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. 2006. J Oral Maxillofac Surg 2007;65(12):2397-410.
  28. Woo S.B., Hellstein J.W., Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144(10):753-61.
  29. Pazianas M., Miller P., Blumentals W.A., et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29(8): 1548-58.
  30. Rizzoli R., Burlet N., Cahall D., et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42(5):841-47.
  31. Sarin J., DeRossi S.S., Akintoye S.O. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008;14:277-85.
  32. Allen M.R., Burr D.B. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009;67(1):61-70.
  33. Sarasquete M.E., Gonzalez M., San Migel J.F. et al. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 2009; 15:382-87.
  34. Hellstein J.W., Adler R.A., Edwards B., et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. Executive summary of recommendations from the American Dental Association Council on Scientific Affairs. JADA 2011;142;1243-51.
  35. Durchschlag E., Paschalis E.P., Zoehrer R., et al.Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 2006;(10):1581-90.
  36. Allen M.R., Iwata K., Phipps R., Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006;39(4):872-79.
  37. Iwata K., Alen M.R., Phipps R., Burr D.B. Microcrack initiation occurs more easily in vertebrae from beagles treated with alendronate. Bone 2006;38(Suppl):42.
  38. Nieves J.W., Bilezikian J.P., Lane J.M., et al. Fragility fractures of the hip and femur: incidence and Bpatient characteristics. Osteoporos Int 2010;21 (3):399-408.
  39. Bianchi G., Felsenberg D., Czerwinski E., et al. Efficacy of IV ibandronate is maintained over 5 years: the DIVA LTE study. Ann Rheum Dis 2009;68(3):494.
  40. Bilezikian J., Kemes A., Silverman S., Cosman F. Subtrochanteric fracture reports coincident with risedronate use. J Bone Miner Res 2009;24(1). http:/www.asbmr.org/Meetings/Annual Meeting/AbstractDetail.aspx?aid=0367cfaa-4d0d-47d8-a57a-ff76098839a2.
  41. Ing-Lorenzini K., Desmeules J., Plachta O., et al. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009;32(9):775-85. doi: 10.2165/00002018-200932090-00002.
  42. European Medicines Agency. 2009. Asses-sment report for Fosavance. EMEA/CHMP/188952/ 2009.http:/www.ema.europa.eu/docs/en_GB/ document_library/EPAR_Assessment_report_ Variation/human/00024252.pdf.
  43. US Food and Drug Administration (FDA) (2010) FDA drug safety communi: ongoing safety review of oral bisphosphonates and atypical subtrochanteric fractures. http:/www. fda.gov/Drugs/DrugsSafety/PostmarketdrugS a fetyIn formation for-PatientsandProviders/ucm 203891.htm.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies